Taiwan Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1995
Buy Report View Sample

Published: July 25, 2022 Report Code: GDHC0080CHR-ST

Select Item

Taiwan Healthcare Market Overview

Taiwan pharmaceutical market size was $2.9 billion in 2021. The market grew at a CAGR of more than 3% during 2015-2018.  Increasing social awareness of health and well-being, a growing aging population, government efforts like biotechnology parks to promote foreign investment, and fast improvements in healthcare technology and digital health are driving the Taiwan pharmaceutical business. Pharmaceutical expansion is hindered by the National Health Insurance Administration’s (NHIA’s) use of medication price controls to curb healthcare costs.

Taiwan Healthcare (Pharma and Medical Devices) Market Analysis

For more pharmaceutical insights, download a free report sample

Taiwan medical devices market size was $2.7 billion in 2021. The market is expected to grow at a CAGR of more than 3% during the period 2022-2027. In March 2022, Taiwan’s Wistron Medical Technology digitized an AI-based dialysis management system, the “Best Shape Chronic Kidney Disease Care,” which can transmit warnings by detecting a drop in blood pressure in terminal-stage renal patients. It provides great support to frontline health workers and makes optimal care possible.

Taiwan Healthcare (Pharma and Medical Devices) Market Analysis

For more medical devices insights, download a free report sample

Market Dynamics in the Taiwan Pharmaceutical Market

  • The Taiwan pharmaceutical market is heavily reliant on imported drugs. Most pharma manufacturing facilities in Taiwan are either in Tainan, a city on Taiwan’s southwest coast, or around Taiwan’s capital city, Taipei, in the far north of the country. They are particularly concentrated in Taoyuan and new Taipei.
  • There is a lack of international pharma companies and contract manufacturing organizations (CMOs) in Taiwan, particularly in the eastern-most counties like Pingtung, Taitung, and Hualien, where there are no locations registered with the FDA or European Medicines Agency (EMA). Yilan, which borders new Taipei, only has one industrial facility, operated by Sinphar Pharmaceutical (Dongshan, Taiwan).

Key Segments in the Taiwan Pharmaceutical Market

The key segments in the Taiwan pharmaceutical market are generics, biologics, biosimilars, and over-the-counter (OTC). The Taiwan Generic Pharmaceutical Association (TGPA) is a non-profit organization established in April 2007. It represents manufacturers and distributors of finished generic pharmaceutical products and active pharmaceutical chemicals, and suppliers of other goods and services to the generic pharmaceutical industry. Since 2015, the TGPA has been a member of the International Generic and Biosimilar Medicines Association (IGBA).

Key Players in the Taiwan Pharmaceutical Market

The key players in the Taiwan pharmaceutical market are F. Hoffmann-La Roche Ltd. (Roche), Sanofi, Merck KGaA (Merck), GlaxoSmithKline (GSK), CCPC, and Sinphar Pharmaceutical.

  1. Hoffmann-La Roche Ltd. (Roche)
  2. Hoffmann-La Roche Ltd. (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases including auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases.

Sanofi

Sanofi is a healthcare company that researches, develops, manufactures, and markets a wide range of medicines and vaccines. It has operations across Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi’s headquarters are located in Paris, France. In Taiwan, it operates from Taipei.

Merck KGaA (Merck)

Merck KGaA (Merck) is a science and technology company that discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility.

 Key Segments in the Taiwan Medical Devices Market

The key segments in the Taiwan medical devices market are cardiovascular devices, hospital supplies, nephrology and urology devices, orthopedic devices, diabetes care devices, and others.

Taiwan Medical Devices Market, by Segments

Taiwan Medical Devices Market, by Segments

For more insight on the medical devices segments, download a free report sample

Key Players in the Taiwan Medical Devices Market

The key players in the Taiwan medical devices market are Fresenius, Medtronic, Stryker, DePuy Synthes, TaiDoc Technology.

Fresenius

Fresenius is a global healthcare group that offers products and services for dialysis, hospitals, and outpatient treatment. It has major manufacturing plants in the US, Germany, China, Sweden, and Japan. The company’s headquarters are located in Bad Homburg, Hessen, Germany. In Taiwan, its office is in Taipei city, Taiwan.

Stryker

Stryker is a medical technology company that manufactures an array of orthopedic, medical and surgical, and neurotechnology and spine products and allied services. The company offers products to doctors, hospitals, and other healthcare facilities. Stryker’s headquarters are located in Kalamazoo, Michigan, US. In Taiwan, Stryker operates from Taipei.

DePuy Synthes

DePuy Synthes is a subsidiary of Johnson & Johnson. It is a medical devices company that provides products for orthopedic procedures. The company offers its products to physicians, hospitals, surgeons, and caregivers, among others. DePuy Synthes’s headquarters are located in Raynham, MA, US. In Taiwan, its offices are located in Taipei.

Market report overview of pharmaceutical market in Taiwan

Market size 2021 $2.9 billion
CAGR % (2013-2018) >3%
Key segments Generics, Biologics, Biosimilars, and Over-The-Counter (OTC)
Major players F. Hoffmann-La Roche Ltd. (Roche), Sanofi, Merck KGaA (Merck), GlaxoSmithKline (GSK), CCPC, and Sinphar Pharmaceutical

Market report overview of medical devices market in Taiwan

Market size 2021 $2.7 billion
CAGR% (2022-2027) >3%
Key segments Cardiovascular Devices, Hospital Supplies, Orthopedic Devices, Nephrology and Urology Devices, Diabetes Care Devices, and Others
Major players Fresenius, Medtronic, Stryker, DePuy Synthes, and TaiDoc Technology

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Taiwan, and includes:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Roche, Sanofi, Merck, GSK, and CCPC.
  • Profiles and SWOT analyses of the major players in the medical device market: Fresenius, Medtronic, Stryker, Depuy Synthes, and TaiDoc.
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices.
  • Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure.
  • An overview of the opportunities for and challenges to growth in the Taiwan healthcare market.

Reasons to Buy

  • This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving Taiwan healthcare market

  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Taiwan healthcare market in the future

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about the Taiwan Healthcare Market

2.3 Key Highlights: Healthcare Startups in Taiwan

2.4 Key Events: Taiwan Pharmaceutical News 2016–22

2.5 Key Events: Taiwan Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2021–22

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, Taiwan, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Taiwan

3.5 Pharmaceutical Market – Market Segments

3.6 Pharmaceutical Market – Market Segment: Generic Drugs, Taiwan

3.7 Pharmaceutical Market – Market Segment: Biologics and Biosimilars, Taiwan

3.8 Pharmaceutical Market – Market Segments, Over-the-Counter Medicines, Taiwan

3.9 COVID-19 Epidemiology, Taiwan

3.10 COVID-19 Impact and Developments in the Healthcare Market, Taiwan

3.11 COVID-19 Clinical Trials Landscape, Taiwan

3.12 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Device Market – Major Segments

4.3 Medical Device Market – Hospital Supplies Market

4.4 Medical Device Market – Orthopedic Devices Market

4.5 Medical Device Market – Nephrology and Urology Devices Market

4.6 Medical Device Market – Cardiovascular Devices Market

4.7 Medical Device Market – Diabetes Care Devices Market

4.8 Medical Devices Market – Diagnostic Market

4.9 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Taiwan, 2019–22

6.2 Deal Analysis: Medical Device Market, Taiwan, 2019–22

7. HealthTech Landscape

7.1 HealthTech Landscape, Taiwan

7.2 HealthTech Deals Landscape, Taiwan

7.3 Key HealthTech Deals, Taiwan

7.4 Adoption of Technology in Healthcare, Taiwan

7.5 Digital Statistics, Taiwan

7.5 Digital Healthcare Regulations, Taiwan

7.6 Digital Health- Benefits and Risks, Taiwan

8. Market Access

8.1 Overview of Healthcare System, Taiwan

8.2 Reimbursement Landscape, Taiwan

8.3 Overview of Insurance Providers, Public Insurance, Taiwan

8.4 Overview of Insurance Providers, Private Insurance, Taiwan

8.5 Healthcare Spending and Prescription Drug Price Trend, Taiwan

8.6 Pricing Policies, Taiwan

8.7 Market Access: Key Events Timeline, Taiwan, 2010–21

8.8 Regulatory Landscape, Taiwan

8.8.1 Marketing Authorization for Pharmaceutical Products, Taiwan

8.8.2 Marketing Authorization for Medical Devices, Taiwan

8.8.3 Pharmaceutical and Medical Device Establishment Regulations, Taiwan

8.8.4 Intellectual Property Rights, Patent, Taiwan

8.8.5 Intellectual Property Rights, Trademark, Taiwan

8.8.6 Clinical Trial Regulation Process, Taiwan

8.8.7 Pharmaceutical Clinical Trials Landscape, Taiwan

8.8.8 Medical Device Clinical Trials Landscape, Taiwan

8.8.9 Pharmaceutical Import and Export, Taiwan

8.8.10 Pharmaceutical Advertising Regulations, Taiwan

8.8.11 Pharmacy Regulations, Taiwan

8.8.12 Labeling and Packaging Regulations, Taiwan

9. Country Healthcare Landscape

9.1 Healthcare Policy Highlights, Taiwan

9.2 Healthcare Facilities, Taiwan

9.3 Life Expectancy and Immunization Rate, Taiwan

9.4 Environmental Health, Taiwan

9.5 Healthcare Personnel, Taiwan

9.6 Disease Burden, Taiwan

9.7 Healthcare Expenditure, Taiwan

9.8 Healthcare Spending Components and Pharmaceutical Spending, Taiwan

10 Trade Associations, Taiwan

11 Trade Fairs, Taiwan

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Role of government agencies working against counterfeit medicines, Taiwan, 2022

Table 2: COVID-19 indicators, global and Taiwan, 2022

Table 3: COVID-19-related travel restrictions, Taiwan, 2020–22

Table 4: Authorized COVID-19 vaccines, Taiwan, 2020–22

Table 5: Pipeline COVID-19 vaccines, Taiwan, 2020–22

Table 6: Available COVID-19 IVD products, Taiwan, 2020–22

Table 7: Pipeline COVID-19 IVD products, Taiwan, 2020–22

Table 8: Medical devices market, major segments ($M), Taiwan, 2021

Table 9: Hospital supplies market, revenue ($M) and market share (%) of major companies, Taiwan, 2021

Table 10: Hospital supplies market, revenue ($M) and market share (%) of major companies, Taiwan, 2021

Table 11: Nephrology and urology devices market, revenue ($M) and market share (%) of major companies, Taiwan, 2021

Table 12: Cardiovascular devices market, revenue ($M) and market share (%) of major companies, Taiwan, 2021

Table 13: Diabetes care devices market, revenue ($M) and market share (%) of major companies, Taiwan, 2021

Table 14: Premium contribution ratios under NHI system, Taiwan, 2022

Table 15: Coinsurance for inpatient care, Taiwan, 2022

Table 16: Comparison of private health insurance types, Taiwan, 2022

Table 17: Registration fee structure for new drug application ($), Taiwan, 2022

Table 18: Schedule of patent fees, Taiwan, 2022

Table 19: Schedule of trademark fees, Taiwan, 2022

Table 20: Trade fairs, Taiwan, 2022

Figures

Figure 1: Pharmaceutical market (based on domestic production), revenue ($B), Taiwan, 2015–21

Figure 2: Medical devices market, revenue ($B), Taiwan, 2016–21

Figure 3: Healthcare start-ups in Taiwan, 2022

Figure 4: Country profile, Taiwan, 2022

Figure 5: Pharmaceutical market revenue ($B, based on domestic production), Taiwan, 2015–21

Figure 6: Pharmaceutical market (based on domestic production), revenue forecast ($B), Taiwan, 2022–26

Figure 7: Pharmaceutical exports ($M), Taiwan, 2011–21

Figure 8: Top export partners, Taiwan, 2021

Figure 9: Pharmaceutical imports ($B), Taiwan, 2011–21

Figure 10: Top import partners, Taiwan, 2021

Figure 11: Framework of the cross-departmental task force on counterfeit medicines in Taiwan, 2022

Figure 12: Major generic drug companies, Taiwan, 2022

Figure 13: Major domestic OTC manufacturers, Taiwan, 2022

Figure 14: COVID-19 (cumulative number of cases), Taiwan, 2020–22

Figure 15: COVID-19 (cumulative number of deaths), Taiwan, 2020–22

Figure 16: COVID-19 fiscal stimulus timeline, Taiwan, 2020–22

Figure 17: COVID-19 stringency index, Taiwan, 2020–22

Figure 18: COVID-19 containment and health index, Taiwan, 2020–22

Figure 19: Total number of vaccine doses administered by brand, Taiwan, 2021–22

Figure 20: COVID-19 vaccine dose administration (number of administered vaccine doses), Taiwan, 2021–22

Figure 21: COVID-19 clinical trials sponsors by count, Taiwan, 2020–22

Figure 22: COVID-19 clinical trials count by phase, Taiwan, 2020–22

Figure 23: COVID-19 clinical trials count by trial status, Taiwan, 2020–22

Figure 24: Medical devices market, revenue ($B), Taiwan, 2016–21

Figure 25: Medical devices market, revenue forecast ($B), Taiwan, 2022–27

Figure 26: Medical devices market, major segments (%), Taiwan, 2021

Figure 27: Hospital supplies market, revenue ($M), Taiwan, 2017–25

Figure 28: Hospital supplies market, market share of major players (%), Taiwan, 2021

Figure 29: Orthopedic devices market, revenue ($M), Taiwan, 2017–25

Figure 30: Orthopedic devices market, market share of major players (%), Taiwan, 2021

Figure 31: Nephrology and urology devices market, revenue ($M), Taiwan, 2017–25

Figure 32: Nephrology and urology devices market, market share of major players (%), Taiwan, 2021

Figure 33: Cardiovascular devices market, revenue ($M), Taiwan, 2017–25

Figure 34: Cardiovascular devices market, market share of major players (%), Taiwan, 2021

Figure 35: Diabetes care devices market, revenue ($M), Taiwan, 2017–25

Figure 36: Diabetes care devices market, market share of major players (%), Taiwan, 2021

Figure 37: Diagnostic market, revenue ($M), Taiwan, 2016–21

Figure 38: Diagnostic market, revenue ($M), Taiwan, 2022–27

Figure 39: Medical devices market, revenue ($B) of major companies, Taiwan, 2021

Figure 40: Deals value and deal count, pharmaceutical market, Taiwan, 2019–22

Figure 41: Deals value and deal count, quarterly, pharmaceutical market, Taiwan, 2019–22

Figure 42: Deals value and deal count, subtypes, pharmaceutical market, Taiwan, 2019–22

Figure 43: Top therapy areas by deal value ($M), pharmaceutical market, Taiwan, 2019–22

Figure 44: Top therapy areas by deal count, pharmaceutical market, Taiwan, 2019–22

Figure 45: M&A deals by quarter (by value and by number), pharmaceutical market, Taiwan, 2019–22

Figure 46: VC deals by quarter (by value and by number), pharmaceutical market, Taiwan, 2019–22

Figure 47: Deals value and deal count, medical devices market, Taiwan, 2019–22

Figure 48: Deals value and deal count, quarterly, medical devices market, Taiwan, 2019–22

Figure 49: Deals value and deal count, subtypes, medical devices market, Taiwan, 2019–22

Figure 50: Top equipment sectors by deal value ($M), medical devices market, Taiwan, 2019–22

Figure 51: Top equipment sectors by deal count, medical devices market, Taiwan, 2019–22

Figure 52: M&A deals by quarter (by value and by number), medical devices market, Taiwan, 2019–22

Figure 53: VC deals by quarter (by value and by number), medical devices market, Taiwan, 2019–22

Figure 54: Digital Government 2.0 Program (2021-25), objectives, Taiwan, 2021

Figure 55: Deals value ($M), Healthtech, Taiwan, 2019–22

Figure 56:Deal count (number of deals), Healthtech, Taiwan, 2019–22

Figure 57: Overview of healthcare system, Taiwan, 2022

Figure 58: HTA assessment for application of NHI new drug listing, Taiwan, 2022

Figure 59: OOP expenditure (% of current expenditure on health), Taiwan, 2013–20

Figure 60: Consumer price index in healthcare sector (Base Year 2016=100) , Taiwan, 2013–21

Figure 61: Organizational structure of TFDA, Taiwan, 2022

Figure 62: Organizational structure of center for drug evaluation, Taiwan, 2022

Figure 63: New drug approval process, regulatory landscape, Taiwan, 2022

Figure 64: Generics drug review process, Taiwan, 2022

Figure 65: Drug review process for NDA, Taiwan, 2022

Figure 66: Key elements, Medical Device Act, Taiwan, 2022

Figure 67: Total product life cycle management process, Taiwan, 2022

Figure 68: Regulatory requirement for medical devices, Taiwan, 2022

Figure 69: Marketing authorization procedure for medical devices, Taiwan, 2022

Figure 70: Clinical trial regulation process for an investigational new drug, Taiwan, 2022

Figure 71: Pharmaceutical clinical trials count by trial status, Taiwan, 2020–22

Figure 72: Pharmaceutical clinical trials count by therapy areas, Taiwan, 2020–22

Figure 73: Pharmaceutical clinical trials count by phase, Taiwan, 2020–22

Figure 74: Top five pharmaceutical clinical trials sponsors by count, Taiwan, 2020–22

Figure 75: Medical devices clinical trials count by trial status, Taiwan, 2020–22

Figure 76: Medical devices clinical trials count by therapeutic areas, Taiwan, 2020–22

Figure 77: Medical devices clinical trials count by indication, Taiwan, 2020–22

Figure 78: Top five medical devices clinical trials sponsors by count, Taiwan, 2020–22

Figure 79: Number of hospitals, Taiwan, 2011–21

Figure 80: Number of diagnostic equipment units (per 100,000 population), Taiwan, 2015–22

Figure 81: Number of clinics (per 1000 population), Taiwan, 2011–21

Figure 82: Hospitals (by Standard of Care), Contracted by NHIA, Taiwan, 2013–20

Figure 83: Hospital Beds (per 10,000 population), Taiwan, 2011–21

Figure 84: Number of Hospital Beds (by Specialty Care), Taiwan, 2020

Figure 85: Immunization coverage (%), Taiwan, 2020

Figure 86: Life expectancy at birth (years), Taiwan, 2013–21

Figure 87: CO2 emissions (tons per capita), Taiwan, 2011–21

Figure 88: Physicians (per 10,000 population), Taiwan, 2011–21

Figure 89: Nurses (per 10,000 population), Taiwan, 2011–21

Figure 90: Pharmacists (per 10,000 population), Taiwan, 2011–21

Figure 91: Dentists (per 10,000 population), Taiwan, 2011–21

Figure 92: Major causes of mortality (per 100,000 population), Taiwan, 2020

Figure 93: Major causes of male mortality (per 100,000 population), Taiwan, 2020

Figure 94: Major causes of female mortality (per 100,000 population), Taiwan, 2020

Figure 95: Healthcare expenditure as percentage of GDP (%), Taiwan, 2011–20

Figure 96: Public-private share (% of total health spending), Taiwan, 2011–20

Figure 97: Pharmaceutical spending (% of GDP), Taiwan, 2013–20

Figure 98: Current healthcare expenditure (per capita, $B), Taiwan, 2011–20

Figure 99: Share of national health expenditure (by financial resources), Taiwan, 2020

Frequently asked questions

Taiwan Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape standard reports
Currency USD
$1,995

Can be used by individual purchaser only

Most Popular
$2,995

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Taiwan Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Taiwan Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape in real time.

  • Access a live Taiwan Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more